For each pathology (Alzheimer’s, Parkinson’s, Huntington’s diseases and multiple sclerosis), NeurATRIS provides state-of-the-art platforms and complementary models (cells, animals) enabling the screening, the characterization, the evaluation and validation up to patients (phase II) of the most promising therapies.
NeurATRIS gives an access to powerful range of expertise and equipment through a one-stop shop covering the entire value chain of drug and biomarker discovery.
ALZHEIMER / PARKINSON / HUNTINGTON / MULTIPLE SCLEROSIS |
|||
 |
|
|
|
|
|
|
|
PLATFORMS |
|
|
NEUROIMAGING: PET, MRI, PET-CT, PET-MRI, SPECT |
|
| COGNITION AND BEHAVIOR: Memory, language, motivation, movement, muscular strength | |
| THERAPEUTIC APPROACHES: gene transfer, cell graft, aptamers, neurosurgery | |
| ELECTROPHYSIOLOGY: patch recording, MEG and EEG, recordings from cell cultures, brain slices | |
| COMPLEMENTARY EXPERTISE: ex vivo imaging, HTS, applied immunology, high-throughput real time PCR, biochemistry, proteomics, pharmacokinetics, etc. | |
| BIOSAFETY: BSL1, 2, 3 for neurosurgery, imaging, histopathology, behavior, etc. |
